When it pays for itself
Updated
The breakeven structure here is unusual because a large share of the cost is per formula rather than per unit or per business.
Three breakevens
The batch: units to cover that run's ingredients and packaging. Reached quickly.
The product: units to cover that formula's identity testing, potency assay, uniformity work and the records behind it. Specific to this category.
The business: everything above plus equipment, insurance, packaging minimums and your time.
Per-formula costs dominate
Because testing is per formula, every product you add restarts a hill. A range of six is six separate breakevens, and the ones that do not sell never reach the top of theirs.
That is a different structure from a category where a variant costs a label. Here it costs testing, a supplier qualification if it brings a new material, and months of turnaround before the first compliant unit exists.
Working the number
Per product: total the per-formula testing plus the share of packaging minimums, divide by gross margin per unit. That is how many units of that product must sell before it has paid for itself.
Compare honestly against expected annual volume. A product needing two years to clear its own testing is a product to reconsider or to fold into another.
What moves it
Fewer products, by a distance the strongest lever.
Higher price, which this category tolerates where the product justifies it and the testing is visible.
Subscription, which raises lifetime value on a product people consume on a schedule and lets you batch to real demand rather than to a forecast.
What barely moves it: cheaper ingredients, which in a category where the ingredient is the claim is also the riskiest place to economize.